Detalhe da pesquisa
1.
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Mov Disord
; 38(3): 386-398, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807624
2.
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.
Br J Clin Pharmacol
; 89(3): 1105-1114, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214216
3.
Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism.
Transpl Int
; 35: 10269, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35651879
4.
The impact of the global COVID-19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysis.
Br J Clin Pharmacol
; 87(3): 837-844, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32668047
5.
Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders.
Int J Mol Sci
; 22(4)2021 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33562713
6.
A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
Clin Transl Sci
; 16(8): 1408-1420, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37177855
7.
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Clin Transl Sci
; 15(8): 2010-2023, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35649245